Today AVAX TECHS INCORPORATED (OTCMKTS:AVXT) Reported Decrease in Shorted Shares

December 7, 2017 - By Dolores Ford

The stock of AVAX TECHS INCORPORATED (OTCMKTS:AVXT) registered a decrease of 97.5% in short interest. AVXT’s total short interest was 100 shares in December as published by FINRA. Its down 97.5% from 4,000 shares, reported previously.

The stock decreased 5.88% or $0.0001 during the last trading session, reaching $0.0016. About 165,700 shares traded or 120.18% up from the average. AVAX Technologies Inc. (OTCMKTS:AVXT) has 0.00% since December 7, 2016 and is . It has underperformed by 16.70% the S&P500.

AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company has market cap of $1.10 million. The companyÂ’s product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It currently has negative earnings. It also develops LungVax for the treatment of non-small cell lung cancer.

More notable recent AVAX Technologies Inc. (OTCMKTS:AVXT) news were published by: Bizjournals.com which released: “Philadelphia biotech firm resolves debt dispute with cancer hospital” on August 05, 2015, also Prnewswire.com with their article: “AVAX Technologies Announces Results Of Its OVAX, Ovarian Cancer Vaccine, Phase …” published on January 26, 2016, Seekingalpha.com published: “Cancer Immunotherapy: A Roundtable Discussion” on June 30, 2011. More interesting news about AVAX Technologies Inc. (OTCMKTS:AVXT) were released by: Bizjournals.com and their article: “​Five things you don’t know about Jeff Jonas, CEO of Sage Therapeutics” published on June 12, 2015 as well as Prnewswire.com‘s news article titled: “AVAX Technologies, Inc. Announces the Appointment of Chief Executive Officer” with publication date: October 19, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.